

JENNY ZHOU, PH.D.
Vice President

Office (London): +44 20 3480 7931
Office (Beijing): +86 10 6587 6200
Fax (London): +44 20 3480 7901
Jenny.Zhou@analysisgroup.com

1 Angel Court
London EC2R 7HJ
United Kingdom

No.2 Jianguomenwai Avenue
Unit 3101, L31, Yintai Office Tower C
Chaoyang, Beijing, 100022, China

Dr. Zhou is a health economist with extensive experience in health economics and outcomes research. Her expertise includes economic evaluation, health technology assessment, and comparative effectiveness research using clinical and real-world evidence. Dr. Zhou has developed evidence submissions – including systematic literature reviews, indirect treatment comparisons, and cost-effectiveness analyses – for health technology appraisals in the UK, EU, and Canada. She also has extensive experience supporting clients through the ICER review process in the US. Dr. Zhou’s additional research has involved assessing disease burden of illness and treatment patterns using various databases; conducting patient and physician surveys and developing pharmaceutical pricing strategies based on early stage modeling. Her experience encompasses a wide range of therapeutic areas, including oncology and hematology, rare bleeding disorders, genetic diseases, autoimmune diseases, mental health disorders, cardiovascular diseases, and infectious diseases. Dr. Zhou’s work has been published in many peer-reviewed journals and featured at numerous conferences.

EDUCATION

2011 Ph.D., pharmaceutical economics and policy, University of Southern California
2008 M.S., pharmaceutical economics and policy, University of Southern California
2006 M.S., neuroscience, University of Southern California
2003 Bachelor of Medicine, Fudan University, Shanghai Medical College (formerly Shanghai Medical University)

PROFESSIONAL EXPERIENCE

2011–Present Analysis Group
Vice President (2019–Present)
Manager: Health economics and outcomes research (2015–2018)
Associate: Health economics and outcomes research (2011–2014)

2003–2011 University of Southern California; Los Angeles, CA
Research Assistant: Hemophilia utilization group study (2007–2011)
Baxter Research Fellow: Grant from Baxter Healthcare Corp. (2008–2011)
Teaching Assistant: Department of Biology (2005–2006)
Research Assistant: Longevity Institute (2003–2006)

Summer 2009 Analysis Group

Associate Intern

2001–2002 Zhongshan Hospital; Shanghai, China
Clinical Intern

SELECTED PUBLICATIONS

Peer-Reviewed Journals

- Goldschmidt J, Hart L, Scott J, Boykin K, Bailey R, Heritage T, Lopez-Gonzalez L, **Zhou ZY**, Edwards ML, Monnette A, Ogbonnaya A, Deyoung K, Venkatesetty D, Shi P, Aton L, Huang H, Conkling PR, Gordan L. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy. *Adv Ther.* 2023 Oct; 40(10):4189-215.
- Bensink ME, Goldschmidt D, **Zhou ZY**, Wang K, Liebllich R, Bunke CM. Kidney Failure Attributed to Focal Segmental Glomerulosclerosis: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden. *Kidney Med.* 2023 Nov. DOI: 10.1016/j.xkme.2023.100760.
- Bensink ME, Goldschmidt D, **Zhou ZY**, Wang K, Liebllich R, Bunke, MC. Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden. *Kidney Med.* 2023 Nov. DOI: 10.1016/j.xkme.2023.100759
- Huang M, A Fasching P, Haiderali A, Xue W, Yang C, Pan W, **Zhou ZY**, Hu P, Chaudhuri M, Le Bailly De Tillegem C, Cappoen N, O'Shaughnessy J. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States. *Adv Ther.* 2023 Mar;40(3):1153-70.
- Brunner AM, Huggar D, Copher R, **Zhou ZY**, Zichlin ML, Anderson A, Downes N, McBride A. Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database. *Leuk Res.* 2023 Sep;132:107353.
- Lu X, **Zhou ZY**, Xin Y, Wang MJ, Gray E, Jairath V, Lindsay JO. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis. *Inflamm Bowel Dis.* 2023;izad037.
- Huang M, Fasching P, Haiderali A, Pan W, Gray E, **Zhou ZY**, Hu P, Chaudhuri M, Bailly De Tillegem CL, Cappoen N, O'Shaughnessy J. Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer. *Immunotherapy.* 2022;14(13):1027-41.
- Loong HH, Wong CKH, Chan CPK, Chang A, **Zhou ZY**, Tang W, Gibbs M. Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia. *JTO Clin Res Rep.* 2022 Feb;3(3):100290.
- Pennell NA, Mutebi A, **Zhou ZY**, Ricculi ML, Tang W, Wang H, Guerin A, Arnhart T, Culver KW, Otterson GA. Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model. *JCO Precis Oncol.* 2019 Dec;3:1-9.

- Bensimon AG, **Zhou ZY**, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibáñez R. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. *J Med Econ*. 2019;22(10):981-93.
- Zhou Z, Fan Y, Tang W, Liu X, Thomason D, **Zhou ZY**, Macaulay D, Fischer A. Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States. *J Rheumatol*. 2019;46(8):920-27.
- **Zhou ZY**, Tang W, Villa KF. Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant. *Clinicoecon Outcomes Res*. 2018 Dec;11:13-22.
- Zhou Z, **Zhou ZY**, Kellar SS, Sikirica V, Xie J, Grebla R. Treatment patterns among adults with ADHD receiving long-acting therapy. *Am J Manag Care*. 2018 Jul;24(8 Spec No.):SP329-37.
- Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculli ML, **Zhou ZY**, Signorovitch J. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. *Adv Ther*. 2018;35(7):1035-48.
- **Zhou ZY**, Mutebi A, Han S, et al. Cost-effectiveness of Ceritinib in Previously Untreated Anaplastic Lymphoma Kinase-positive Metastatic Non-small Cell Lung Cancer in the United States. *J Med Econ*. 2018 Jun;21(6):577-86.
- Zhou Z, **Zhou ZY**, Kelkar SS, Sikirica V, Xie J, Grebla R. Medication Use in Adults with Attention Deficit/Hyperactivity Disorder in a Commercially-insured Population in the United States. *Curr Med Res Opin*. 2018 Apr;34(4):585-92.
- Hurry M, **Zhou ZY**, Zhang J, Zhang C, Fan L, Rebeira M, Xie J. Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada. *J Med Econ*. 2016 Oct;19(10):936-44.
- Liu G, Zhang J, **Zhou ZY**, Li J, Cai X, Signorovitch J. Association Between Time to Progression and Subsequent Survival in Ceritinib-treated Patients with Advanced ALK-positive Non-small Cell Lung Cancer. *Curr Med Res Opin*. 2016 Nov;32(11):1911-18.
- Tan DS, Araújo A, Zhang J, Signorovitch J, **Zhou ZY**, Cai X, Liu G. Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. *J Thorac Oncol*. 2016 Sep;11(9):1550-7.
- Strand V, Husni E, Griffith J, **Zhou ZY**, Signorovitch J, Ganguli A. Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. *Rheumatol Ther*. 2016 Dec;3(2):305-22.
- **Zhou ZY**, Griffith J, Du EX, Chin D, Betts KA, Ganguli A. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis. *Adv Ther*. 2016 May;33(5):807-23.
- Betts KA, Griffith J, Friedman A, **Zhou ZY**, Signorovitch JE, Ganguli A. An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate and Apremilast in the Treatment of Methotrexate-naïve Patients with Psoriatic Arthritis. *Curr Med Res Opin*. 2016;32(4):721-9.

- **Zhou ZY**, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J. Health Resource Use and Costs of Vilazodone and Other Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder. *J Med Econ*. 2015;18(11):919-29.
- Xie J, Hao Y, **Zhou ZY**, Qi CZ, De G, Glück S. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective. *Clin Breast Cancer*. 2015;15(5):e263-76.
- **Zhou ZY**, Koerper M, Johnson K, et al. Burden of Illness: Direct and Indirect Costs among Persons with Hemophilia in the United States. *J Med Econ*. 2015;18(6):457-65.
- Hurvitz S, Guerin A, Brammer M, Guardino E, **Zhou ZY**, Latremouille Viau D, Wu EQ, Lalla D. Investigation of Adverse-Event-Related Costs for Patients with Metastatic Breast Cancer in a Real-World Setting. *Oncologist*. 2014;19(9):901-8.
- Niu X, Poon JL, Riske B, **Zhou, ZY**, et al. Physical Activity and Health Outcomes in Persons with Haemophilia B. *Haemophilia*. 2014;20(6):812-21.
- Yang H, Chaudhari P, **Zhou ZY**, et al. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex in the Treatment of Invasive Fungal Infections in the United States. *Appl Health Econ Health Pol*. 2014;12(1):85-93.
- **Zhou ZY**, Hay JW. Efficacy of Bypassing Agents in Patients with Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis. *Clin Ther*. 2012;34(2):434-45.
- Poon JL, **Zhou ZY**, Doctor JN, et al. Quality of Life in Hemophilia A: Hemophilia Utilization Group Study Va (HUGS-Va). *Haemophilia*. 2012;18(5):699-707.
- Johnson KA, **Zhou ZY**. Costs of Care in Hemophilia and Possible Implications of Health Care Reform. *Hematology Am Soc Hematol Educ Program*. 2011;2011:413-8.
- Hay JW, **Zhou ZY**. Economic Comparison of APCC vs rFVIIa for Mild-to-Moderate Bleeding Episode in Hemophilia Patients with Inhibitors. *Haemophilia*. 2011;17(5):e969-74.
- **Zhou ZY**, Riske B, Forsberg AD, et al. The Association of Social, Demographic, Insurance, and Clinical Factors with Self-Reported Barriers to Hemophilia Care in Patients with Factor VIII Deficiency. *Am J Prev Med*. 2011;41(6 Suppl 4):S346-53.
- **Zhou ZY**, Wu J, Baker J, et al. Hemophilia Utilization Group Study-Part Va (HUGS Va): design, methods and baseline data. *Haemophilia*. 2011;17(5):729-36.
- Hay JW, **Zhou ZY**. Systematic Literature Review of Economics Analysis on Treatment of Mild-to-Moderate Bleeds with aPCC Versus rFVIIa. *J Med Econ*. 2011;14(4):516-25.
- Hay JW, **Zhou ZY**. Commentary on Knight, Et Al.: A Systematic Review of the Cost-Effectiveness of rFVIIa and APCC in the Treatment of Minor/Moderate Bleeding Episodes for Haemophilia Patients with Inhibitors. *Haemophilia*. 2010;16(2):366-8; discussion 369-71.
- Gao YQ, Gao H, **Zhou ZY**, Lu SD, Sun FY. Expression of Transient Receptor Potential Channel 4 in Striatum and Hippocampus of Rats Is Increased After Focal Cerebral Ischemia. *Sheng Li Xue Bao*. 2004;56(2):153-7.

Workshops

- Advancements in methods of survival benefit estimation for novel oncology drugs and their applications in ICER reviews. Educational Symposium at ISPOR 2018, Baltimore Maryland, May 19–23, 2018
- Evaluating survival benefits in technology appraisals of innovative oncology drugs: challenges and practical solutions. Educational Symposium at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017

Selected Poster or Podium Presentations

- Gong W, Bensink M, Chai X, Xie Y, Gao S, Hendry B, Mercer A, **Zhou J**, Rovin B, Barratt J. Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study With UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd. Poster presentation at National Kidney Foundation Spring Clinical Meetings 2024, Long Beach, CA, May 14–18, 2024
- Hanna K, Palaia J, Ejzykowicz F, Patel D, Rosenblatt L, **Zhou J**, Yang F, Garcia-Hort V. Cost-per-outcome analysis of nivolumab plus relatlimab vs BRAF/MEK inhibitor combinations for first-line treatment of patients with BRAF-mutant advanced melanoma. Poster presentation at Academy of Managed Care Pharmacy (AMCP) 2024, New Orleans, LA, April 16–19, 2024
- Bensink ME, Sullivan SD, **Zhou J**. Modeling long-term outcomes for patients with immunoglobulin A nephropathy from short-term proteinuria data. Poster presentation at AMCP 2024, New Orleans, LA, April 16–19, 2024
- Ejzykowicz F, Palaia J, Steffen D, Mattera M, **Zhou J**, Ratto B, Moshyk A, Patel D, Salvatore A, Garcia-Horton V. Matching-Adjusted Indirect Comparison (MAIC) of Nivolumab + Relatlimab (NIVO+RELA) Vs. BRAF/MEK Inhibitors for First-Line Treatment of BRAF-Mutant Advanced/Metastatic Melanoma (AMEL). Poster presentation at ISPOR Europe 2023, Copenhagen, Denmark, November 12–15, 2023
- Blakely LJ, **Zhou ZY**, Edwards ML, Sarathy K, Yang F, Roush A, Moore M, Huang H. Burden of myelosuppression in extensive-stage small-cell lung cancer patients receiving chemotherapy: Retrospective analysis of real-world data from Tennessee Oncology. Poster presentation at 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, Boston, MA, October 27–28, 2023
- Ahn D, Park NJ, Locker MC, **Zhou ZY**, Nie X, Wang T, Yu S. Real-world clinical outcomes of cabozantinib (cabo) as a second-line (2L) treatment for advanced hepatocellular carcinoma (aHCC). Poster presentation at European Society for Medical Oncology (ESMO) Congress 2023, Madrid, Spain, October 20–24, 2023
- Yang K-C, Jazic I, Scirica C, **Zhou ZY**, Tang W, Gawade P. Prevalence and disease burden of alpha-1 antitrypsin deficiency in Germany. Poster presentation at European Respiratory Society International Congress 2023, Milan, Italy, September 9–13, 2023
- Schadendorf D, Tawbi HA, Lipson EJ, Hodi FS, Ascierto PA, Larkin J, Lao CD, Grob J, Ejzykowicz F, Moshyk A, Garcia Horton V, **Zhou J**, Xin Y, Palaia J, McDonald L, Keidel S, Salvatore A, Sakkal LA, Long GV. Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO + RELA) versus NIVO plus ipilimumab (NIVO + IPI) in advanced melanoma: An indirect treatment comparison (ITC) using patient-level data (PLD). Poster presentation at 2023 ASCO Annual Meeting, Chicago, IL, June 2–6, 2023

- Bensink M, Goldschmidt D, **Zhou ZY**, Shi S, Lin Y, Shi L. A Retrospective Cohort Study of Veterans Affairs Data: Epidemiology, Treatments, Clinical Outcomes, and Burden of Immunoglobulin A Nephropathy. Poster presentation at ISPOR 2023, Boston, MA, May 7–10, 2023
- Bensink M, Goldschmidt D, **Zhou ZY**, Shi S, Lin Y, Shi L. A Retrospective Cohort Study of Veterans Affairs Data: Epidemiology, Treatments, Clinical Outcomes, and Burden of Focal Segmental Glomerulosclerosis. Poster presentation at ISPOR 2023, Boston, MA, May 7–10, 2023
- Garcia-Horton V, **Zhou ZY**, Moskyk A, Rosenblatt LC, Patel D, Xin Y, Wang Q, Christensen D, Palaia J. Temporal Trends in Adverse Event Costs with Nivolumab + Relatlimab Combination Therapy or Nivolumab Monotherapy for Patients with Unresectable or Metastatic Melanoma. Poster presentation at ISPOR 2023, Boston, MA, May 7–10, 2023
- McBride A, Huggar D, Copher R, **Zhou ZY**, Zichlin ML, Anderson A, Downes N, Brunner AM. P1738: A Seer-Medicare Analysis of the Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents. Poster presentation at European Hematology Association 2022 Hybrid Congress, Vienna, Austria, June 9–17, 2022
- Goldschmidt JH, Weiss J, **Zhou J**, Wang J, Young JA, Lemus Wirtz E, Ruiz J, Huang H, Hart LL. Impact of trilaciclib on multilineage chemotherapy-induced myelosuppression events in patients with extensive-stage small cell lung cancer: Post-hoc analyses of data from randomized clinical trials. Poster presentation at 2022 ASCO Annual Meeting, Chicago IL, June 3–7, 2022
- Ailawadhi S, Ma Q, Jalbert JJ, Zhou M, **Zhou ZY**, Downes N, Briggs A, Chi L, Hampp C, Song X, Noguera-Troise I, Weyne J, Kroog GS, Rodriguez-Lorenc K. Prevalence of ocular comorbidities in patients with multiple myeloma: An analysis of U.S. claims data. Poster presentation at 2022 ASCO Annual Meeting, Chicago, IL, June 3–7, 2022
- Niu X, Goldschmidt D, Edwards ML, Laubmeier K, Nelson M, Chin A, **Zhou J**, Tocco M. Healthcare Resource Use Among Patients Treated with Lurasidone or Cariprazine for Depressive Episodes Associated with Bipolar I Disorder. Poster presentation at ISPOR 2022, Washington, DC, May 16–18, 2022
- Bensink ME, Goldschmidt D, Taiji R, **Zhou J**, Wang K, Lieblich R, Bunke M. A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Focal Segmental Glomerulosclerosis (FSGS). Poster presentation at ISPOR 2022, Washington, DC, May 16–18, 2022
- Bensink ME, Goldschmidt D, Taiji R, **Zhou J**, Wang K, Lieblich R, Bunke M. A USRDS Retrospective Cohort Study: Epidemiology, Treatment Modalities, and Burden of End-Stage Kidney Disease Attributed to Immunoglobulin A Nephropathy. Poster presentation at ISPOR 2022, Washington, DC, May 16–18, 2022
- Abraham I, Xue W, Chen X, **Zhou ZY**, Huang H. Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression (CIM) in Extensive-Stage Small Cell Lung Cancer (ES-SCLC): Economic Evaluation from the Provider and Patient-Caregiver Perspectives in the United States. Poster presentation at ISPOR 2022, Washington, DC, May 16–18, 2022
- Lu X, Gray E, Xin Y, **Zhou ZY**, Jairath V, Lindsay JO. A Matching-Adjusted Indirect Comparison of Filgotinib Versus Tofacitinib for Moderately to Severely Active Ulcerative Colitis. Poster presentation at ISPOR 2022, Washington, DC, May 16–18, 2022

- Fasching PA, Huang M, Haiderali A, Xue W, Pan W, **Zhou ZY**, Hu P, Chaudhuri M, Le Bailly De Tillegem C, Cappoen N, O'Shaughnessy J. Cost Effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage triple-negative breast cancer in the United States. Poster presentation at ESMO Breast Cancer 2022, Berlin, Germany, May 3–5, 2022
- Brunner AM, Huggar D, Copher R, **Zhou ZY**, Zichlin ML, Anderson A, Downes N, McBride A. Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis. Poster presentation at 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, Atlanta, GA, December 11–14, 2021
- Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, **Zhou ZY**, Sievert M. A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma. Poster presentation at 63rd ASH Annual Meeting and Exposition, Atlanta, GA, December 11–14, 2021
- HONUS Advisory Board Members and HONUS Study Team. Humanistic Burden of Rare Kidney Diseases; Understanding the Impact of FSGS and IgAN on Patients and Caregivers: The HONUS Rationale and Study Design. Poster presentation at American Society of Nephrology Kidney Week 2021, November 4, 2021
- Niu X, Laubmeier K, Nelson M, Tocco M, **Zhou J**, Goldschmidt D, Edwards ML. Clinician Preferences in the First-Line Treatment of Depressive Episodes Associated with Bipolar I Disorder. Poster presentation at Neuroscience Education Institute Congress 2021, Colorado Springs, CO, November 4–7, 2021
- Wu E, Xu MK, **Zhou ZY**. A multi-tumor economic evaluation of infusion time and costs associated with a six-weekly dosing schedule for pembrolizumab in the United States. Presentation at AMCP Nexus 2021, Denver, CO, October 18–21, 2021
- Jairath V, Lindsay J, Gray E, Xin Y, **Zhou ZY**, Wang MJ, Lu X. A matching-adjusted indirect comparison of oral filgotinib versus intravenous vedolizumab for moderately to severely active ulcerative colitis. Poster presentation at United European Gastroenterology Week Virtual 2021, October 3–5, 2021
- Richter J, Lin PL, Garcia-Horton V, Guyot P, Singh E, **Zhou ZY**, Sievert M. A matching-adjusted indirect comparison of isatuximab plus carfilzomib and dexamethasone versus daratumumab plus lenalidomide and dexamethasone for relapsed multiple myeloma. Poster presentation at 18th International Myeloma Workshop, Vienna, Austria, September 8–11, 2021
- Qi CZ, **Zhou ZY**, Zichlin ML, Koenigsberg S, Signorovitch J, Clancy Z, Copher R, Niesvizky R. Association Between Costs of Care in Oncology Care Model-Defined Episodes and Overall Survival in Multiple Myeloma. Poster presentation at 17th International Myeloma Workshop, Boston, MA, September 12–15, 2019
- Dabbous O, **Zhou ZY**, Tang C, Harvey M, Wu EQ, Arjunji R. Assessing the Relationship between Lifelong Value and Pricing for Orphan Drugs in Ultra-rare Diseases. Poster presentation at ISPOR 2019, New Orleans, LA, May 18–22, 2019

- Qi CZ, Huang M, Haiderali A, Xie J, **Zhou ZY**, Wu EQ, Fasching P. Association Between Pathological Complete Responses and Long-Term Survival Outcomes Among Triple-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Poster presentation at National Comprehensive Cancer Network Annual Conference, Orlando, FL, March 21–23, 2019
- **Zhou ZY**, Parikh K, Chai X, Rokito A, Udeze C, Xie J, Agarwal A. Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective. Poster presentation at 60th ASH Annual Meeting and Exposition, San Diego, CA, December 1–4, 2018
- Mahajerin A, **Zhou ZY**, Raimundo K, Patel A, Han S, Ji Y, Zhong J, Betts K. Model of Short and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A. Poster presentation at 60th ASH Annual Meeting and Exposition, San Diego, CA, December 1–4, 2018
- Griffin JD, Storm M, Wilhelm K, Boscoe A, Macaulay D, **Zhou ZY**, Faust E, Cheung C. Treatment Patterns and Healthcare Resource Utilization in Patients with Relapsed/Refractory Acute Myeloid Leukemia and a Subset with IDH1-Mutation: A United States Medical Chart Review Study. 60th ASH Annual Meeting and Exposition, San Diego, CA, December 1–4, 2018
- Pennell NA, Mutebi A, **Zhou ZY**, et al. Economic Impact of Next Generation Sequencing vs. Single-gene Testing Strategies to Detect Genomic Alterations in Metastatic NSCLC Using a Decision Analytic Model. Poster presentation at 2018 ASCO Annual Meeting, Chicago, IL, June 1–5, 2018
- Xie J, Knoll S, Slowley A, Bensimon A, Vieira J, Chilcott J, Paisley S, **Zhou ZY**. Cost-effectiveness of ceritinib in previously untreated ALK-positive non-small cell lung cancer in the United Kingdom. Poster presentation at ISPOR 2018, Baltimore, MD, May 19–23, 2018
- Zhou Z, Yu Y, Liu W, Tang W, **Zhou ZY**, Thomason D, Macaulay D, Fischer A. Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients. American Thoracic Society 2018 International Conference, San Diego, CA, May 18–23, 2018
- Thomason D, Yu Y, Zhou Z, Tang W, Liu X, **Zhou ZY**, Macaulay D, Fischer A. Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD). Poster presentation at AMCP Annual Meeting, Boston, MA, April 23–26, 2018
- **Zhou ZY**, Tang W, Villa K. A model estimating work productivity loss due to premature death associated with hepatic veno-occlusive disease/sinusoidal obstruction syndrome among hematopoietic stem cell transplant patients in the United States. Poster presentation at 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO, March 21–23, 2018
- Zhou Z, Yu Y, Tang W, Liu W, Thomason D, **Zhou ZY**, Macaulay D, Fischer A. Burden of illness of systemic sclerosis among commercially insured patients. Poster presentation at 5th Systemic Sclerosis World Congress, Bordeaux, France, February 15–17, 2018
- Ailawadhi S, Parikh K, Zhou Z, Tang W, Clancy Z, Cheung C, **Zhou ZY**, Xie J, Abouzaid S. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A Seer-Medicare analysis. Poster presentation at 59th ASH Annual Meeting and Exposition, Washington, DC, December 9–12, 2017

- **Zhou ZY**, Bensimon A, Cheng J, Dalal A. Budget impact analysis of dabrafenib and trametinib combination therapy in the treatment of BRAF V600E-mutant advanced non-small cell lung cancer in the United States. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017
- Mutebi A, **Zhou ZY**, Ricculli ML, Han S, Xie J, Dalal A, Culver K. Budget impact analysis of first-line ceritinib in the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC) in the United States. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017
- Dalal A, **Zhou ZY**, Tang W, Ricculli ML, Guerin A, Sasane M, Wu K, Culver K, Otterson G, Pennell N. Cost consequence analysis of different gene mutation testing modalities for BRAFV600E mutation in advanced non-small cell lung cancer using a decision analytic model. Poster presentation at ISPOR 20th Annual European Congress, Glasgow, Scotland, November 4–8, 2017
- **Zhou ZY**, Mutebi A, Han S, Bensimon A, Ricculli ML, Xie J, Dalal AA, Culver KW. Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the United States. Poster presentation at AMCP Nexus, Dallas, TX, October 16–19, 2017
- Zhou Z, **Zhou ZY**, Kelkar SS, Xie J, Grebla R. Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US. Poster presentation at AMCP Nexus, Dallas, TX, October 16–19, 2017
- Chaudhuri KR, Terasawa E, Jalundhwala Y, Macaulay D, Ayyagari R, **Zhou ZY**, Marshall T, Chatamra K, Yucel A, Sail K. Non-motor symptoms in advanced Parkinson’s disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis. Poster presentation at 20th International Congress of Parkinson’s Disease and Movement Disorders, Berlin, Germany, June 19–23, 2016
- Abouzaid S, Parikh K, **Zhou ZY**, Zhou Z, Tang W, Xie J, Patel MI. Disparities in treatment patterns and outcomes between Caucasian and African American patients with multiple myeloma (MM). Poster presentation at ASCO Annual Meeting, Chicago, IL, June 3–7, 2016
- Zhang J, Song Y, **Zhou ZY**, Zhang C, Signorovitch J. The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer. Podium presentation at 6th European Lung Cancer Conference, Geneva, Switzerland, April 13–16, 2016
- **Zhou ZY**, Zhang J, Fan L, Zhang C, Xie J. Cost-effectiveness of Ceritinib in the Treatment of Previously Treated Anaplastic Lymphoma Kinase-positive (ALK+) Advanced or Metastatic Non-small Cell lung Cancer in the United Kingdom. Poster presentation at ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015
- **Zhou ZY**, Hurry M, Zhang J, Fan L, Zhang C, Xie J. Cost-effectiveness of Ceritinib in Previously Treated Patients with Crizotinib in Anaplastic Lymphoma Kinase-positive (ALK+) Non-small Cell lung Cancer in Canada. Poster presentation at ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015
- Zhang J, **Zhou ZY**, Cai X, Signorovitch J. Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-small Cell lung Cancer (NSCLC): A Network Meta-Analysis. Poster presentation at ISPOR 18th Annual European Congress, Milan, Italy, November 7–11, 2015

- **Zhou ZY**, Griffith J, Ganguli A, Du EX, Betts K. Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis. Poster presentation at 2015 American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) Annual Meeting, San Francisco, CA, November 6–11, 2015
- Liu G, Zhang J, **Zhou ZY**, Li J, Cai X, Signorovitch J. Time to Progression and Post-Progression Survival in ALK+ Ceritinib-treated NSCLC. Oral presentation at 16th World Conference on Lung Cancer (WCLC 2015), Denver, CO, September 6–9, 2015
- Tan DS, Araujo A, Zhang J, Signorovitch JE, **Zhou ZY**, Cai X, Liu G. Comparative Efficacy of Ceritinib and Crizotinib in Previously Treated Crizotinib-naïve Anaplastic Lymphoma Kinase-positive (ALK+) Advanced or Metastatic Non-small Cell lung Cancer (NSCLC): An Adjusted Indirect Comparison. Poster presentation at ASCO 2015 Annual Meeting, Chicago, IL, May 29–June 2, 2015
- **Zhou ZY**, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A. Economic Evaluation of Timely Versus Delayed Use of Anti-Tumor Necrosis Factor (TNF) Biologics in the Treatment of Psoriatic Arthritis (PsA) in the US. Poster presentation at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015
- **Zhou ZY**, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE. Healthcare Utilization and Costs Among Adults with Major Depressive Disorder Treated with Vilazodone vs. Other Selective Serotonin Reuptake Inhibitors. Poster presentation at ISPOR 20th Annual International Meeting, Philadelphia, PA, May 16–20, 2015
- Xie J, Hao Y, **Zhou ZY**, Qi C, De G, Gluck S. Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States. Poster presentation at AMCP Nexus, Boston, MA, October 7–10, 2014
- Wolff M, **Zhou ZY**, Signorovitch J, Shaw JW and Ganguli A. Cost-Effectiveness Of Different Treatment Sequences Including Adalimumab In The Treat-To-Target Framework For Early Rheumatoid Arthritis In Germany. Oral presentation at ACR/ARHP Annual Meeting, San Diego, CA, October 26–30, 2013
- Zhang J, Pramanik A, Fuentes-Albuero A, Anaya P, Tinajero-Ayala B, **Zhou ZY**, Xie J, Signorovitch J, Fan L. Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2-, Que Fallaron a Los Inhibidores De Aromatasa No Esteroideos (IANES) En México. Poster presentation at ISPOR 4th Latin America Conference, Buenos Aires, Argentina, September 12–14, 2013
- Chaudhari P, Yang H, **Zhou ZY**, et al. Budget Impact Analysis of Liposomal Amphotericin B and Amphotericin B Lipid Complex for Treating Invasive Fungal Infections in Hospitalized Patients. Poster presentation at ISPOR 18th Annual International Meeting, New Orleans, LA, May 18–22, 2013
- **Zhou ZY**, Fan L, Chen E, Xie J, Wu EQ. An Economic Model of Improved Acute Stroke Care in the Management of Acute Ischemic Stroke from a State Medicaid Perspective. Poster presentation at International Stroke Conference, Honolulu, HI, February 5–7, 2013

- Hurvitz SA, Guerin A, Brammer MG, Guardino E, **Zhou ZY**, et al. Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Poster presentation at ASCO Annual Meeting, Chicago, IL, 2012
- Xie JP, **Zhou ZY**, Bai CN, et al. Cost-Effectiveness Analysis of Mirabegron versus Tolterodine Extended Release in the Treatment of Patients with Overactive Bladder in the United States. Poster presentation at ISPOR 15th Annual European Congress, Berlin, Germany, November 3–7, 2012
- Hurvitz SA, Guérin A, Brammer M, Guardino E, **Zhou ZY**, Kaminsky MS, Wu EQ, Lalla D. Comprehensive investigation of adverse event (age)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies. Poster presentation at ISPOR 15th Annual European Congress 2012, Berlin, Germany, November 3–7, 2012
- Yang M, Yang M, Skup M, **Zhou ZY**, et al. Cost-effectiveness of Adalimumab for the Treatment of Crohn's Disease in Germany. Poster presentation at ISPOR 15th Annual European Congress 2012, Berlin, Germany, November 3–7, 2012
- Poon J, Lou M, **Zhou ZY**, et al. Characterizing Excessive School and Work Absenteeism in Hemophilia A. Poster presentation at World Federation of Hemophilia (WFH) World Congress, Paris, France, July 8–12, 2012
- Johnson KA, Curtis R, Koerper M, Lou M, Poon JL, Riske B, **Zhou ZY**. Healthcare Utilization and Cost of Care – Insights from the Hemophilia Utilization Group Study (HUGS). Podium presentation at WFH World Congress, Paris, France, July 8–12, 2012
- Johnson KA, **Zhou ZY**, et al. Burden of Illness: Direct and Indirect Costs Among Persons with Hemophilia A. Poster presentation at 2nd National Conference on Blood Disorders in Public Health, Atlanta, GA, March 10–12, 2012 (Best poster presentation award)
- Poon J, Lou M, **Zhou ZY**, et al. Health Literacy in Persons with Hemophilia B. Poster presentation at 2nd National Conference on Blood Disorders in Public Health, Atlanta, GA, March 10–12, 2012
- Poon J, Lou M, **Zhou ZY**, et al. Sociodemographics, Clinical Characteristics and Health-Related Quality of Life among People with Hemophilia A and B. Poster presentation at National Hemophilia Foundation (NHF) Meeting, Chicago, IL, 2011
- **Zhou ZY**, Hay JW. A systematic review and meta-analysis comparing the efficacy of bypassing agents in hemophilia patients with inhibitors. Poster presentation at the XXIII Congress of the International Society on Thrombosis and Haemostasis 57th Annual SSC Meeting, Kyoto, Japan, July 23–28, 2011
- **Zhou ZY**, Ullman M, Koerper, et al. Characterizing direct costs associated with hemophilia A: a resource-based cost analysis. Poster presentation at ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011 (Best student poster finalist)
- Lou M, **Zhou ZY**, et al. Utilizing a paper standard gamble instrument to assess health utility in patients with hemophilia B. Poster presentation at ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011
- Poon J, Lou M, Doctor J, **Zhou ZY**, et al. Hemophilia-related quality of life in hemophilia B. Poster presentation at ISPOR Annual International Meeting, Baltimore, MD, May 21–25, 2011 (Best student poster finalist)

- **Zhou ZY**, et al. Bleeding episodes and indirect costs among patients with hemophilia A - the Hemophilia Utilization Group Study Part Va (HUGS Va). Podium presentation at NHF Meeting, New Orleans, LA, 2010
- **Zhou ZY**, et al. Health care utilization and cost in persons with factor VIII deficiency: results of the HUGS-Va study. Poster presentation at XXIXth International Congress of the WFH, Buenos Aires, Argentina, July 10–14, 2010
- **Zhou, ZY**, et al. Association of self-reported joint pain and motion limitation with clinical range of motion assessment in patients with hemophilia A. Poster presentation at XXIXth International Congress of the WFH, Buenos Aires, Argentina, July 10–14, 2010
- Lou M, **Zhou ZY**, et al. The Hemophilia Utilization Group Study Part-Vb: characterization of baseline data. Poster presentation at NHF Meeting, New Orleans, LA, May 15–19, 2010
- **Zhou ZY**, et al. One year health care utilization and cost in patients with factor VIII deficiency: first year results, et al. Podium presentation at NHF Meeting, San Francisco, CA, 2009
- **Zhou ZY**, et al. Healthcare utilization in persons with severe hemophilia A on prophylactic vs. episodic replacement. Poster presentation at Hemostasis & Thrombosis Research Society (HTRS) Scientific Symposium, Chicago, IL, 2009 (Young investigator award)
- Hay JW., **Zhou ZY**, Young G. Economic comparison of APCC vs rFVIIa for mild-to-moderate bleeding episode in hemophilia patients with inhibitors. Poster presentation at XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, July 11–16, 2009
- Hay JW, **Zhou ZY**, aPCC versus rFVIIa in treatment of hemophilia patients with inhibitors: a structured review of the pharmacoeconomic literature. Poster presentation at XXII Congress of the International Society of Thrombosis and Haemostasis, Boston, MA, July 11–16, 2009
- **Zhou ZY**, Globe D, Ullman M, et al. Health care utilization and factor cost in hemophilia. Poster presentation at ISPOR Annual International Meeting, Orlando, FL, May 16–20, 2009
- **Zhou ZY**, et al. Health insurance coverage for adults and children with hemophilia: HUGS-V: A. Poster presentation at NHF Meeting, Denver, CO, 2008
- Curtis R, **Zhou ZY**, et al. Hemophilia Utilization Group Study (HUGS V): baseline data and factor utilization. Poster presentation at XXVIII International Congress of the WFH, Istanbul, Turkey, June 1–5, 2008
- **Zhou ZY**, Wu J, Globe D, et al. Factors associated with lower health-related quality of life (HRQOL) in adults with factor VIII deficiency. Poster presentation at ISPOR Annual International Meeting, Toronto, Canada, May 3–7, 2008
- **Zhou ZY**, et al. Hemophilia Utilization Group Study (HUGS V): summary of baseline demographics, clinical characteristics, barriers to care, arthropathy and quality of life. Poster presentation at NHF Meeting, Orlando, FL, 2007
- Riske B, Forsberg A, **Zhou ZY**, et al. Association of social demographics and clinical factors with barriers to hemophilia care in patients with factor viii deficiency. Poster presentation at American Public Health Association (APHA) 135th Annual Meeting, Washington, DC, November 3–7, 2007